Premium
Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group
Author(s) -
Athale Uma H.,
Gibson Paul J.,
Bradley Nicole M.,
Malkin David M.,
Hitzler Johann
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25939
Subject(s) - medicine , minimal residual disease , pediatric oncology , childhood leukemia , leukemia , disease , oncology , family medicine , standard of care , intensive care medicine , pediatrics , lymphoblastic leukemia , cancer
Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk‐adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recommended indications. The proposed MRD recommendations have been endorsed by the MRD Working Group of the Pediatric Oncology Group of Ontario and provide the foundation for a strategy that aims at equitable access to MRD evaluation for children with leukemia.